Merit Medical Systems combines a perfect four-quarter earnings beat streak averaging nearly 13% upside, a maximum Piotroski financial health score of 9 out of 9, and free-cash-flow conversion at 128% of net income — but a confirmed death cross with the 200-day moving average declining at roughly 4% per month represents a hard technical block that makes the setup best suited to patient holders rather than new buyers.
Thesis pillars
- Perfect Earnings Execution Strong Cash Conversion→Stable
- Confirmed Downtrend Blocks Near Term Entry→Stable
- Maximum Financial Health Score→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Merit Medical Systems, Inc. (MMSI) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $90.63, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away).
Merit Medical Systems manufactures proprietary medical devices across two segments — cardiovascular and endoscopy — serving interventional, diagnostic, and therapeutic procedures globally. Revenue comes from direct sales to hospitals and physicians in the U.S. (60% of net sales... Read more
Hold if already holding. Not a fresh buy at $90.63, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away). Chart setup: RSI 52 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 110d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Merit Medical Systems, Inc.
About Merit Medical Systems, Inc.
Merit Medical Systems distributes medical devices across two operating segments — cardiovascular and endoscopy — with U.S. net sales at 60% of consolidated net sales in 2025 and international sales at 40%, led by China as the largest non-U.S. market. The company completed five acquisitions between June 2023 and November 2025, including assets from AngioDynamics, Cook Medical Holdings, and Pentax of America, adding interventional oncology, endoscopy, and spine capabilities. International sales grew 9.1% in 2025.
Merit Medical Systems sells through dedicated direct sales forces in the U.S., targeting physicians, hospitals, and alternate-site facilities, and through more than 500 distributors in mainland China under a modified direct approach that employs company sales personnel alongside distributors. The cardiovascular segment covers peripheral intervention, cardiac intervention, custom procedural solutions, and OEM; the endoscopy segment covers gastroenterology and pulmonary products. Input cost exposure centers on petroleum-based resins and plastics sourced from a limited number of suppliers, with tariff risk on imports from Mexico, Ireland, and China adding manufacturing cost uncertainty. Sterilization of products depends on a relatively small number of third-party service providers; any disruption could delay production and sales. China's volume-based procurement policy, introduced in 2019 and affecting revenues since 2022, continues to pressure pricing in the company's largest international market.
Show full overview
The CEO transition completed in October 2025 — when founder Fred Lampropoulos resigned and was succeeded by Martha Aronson, with Lampropoulos also departing the Board in January 2026 — coincides with integration demands from five acquisitions closed over 29 months. The 10-K cautions that changes in leadership could negatively impact relationships with key customers, suppliers, and investors. Integrating AngioDynamics, EndoGastric Solutions, Cook Medical Holdings, Biolife, and Pentax of America across different therapeutic areas each requires coordinating regulatory, manufacturing, and commercial functions simultaneously.
See also: Healthcare · Medical Instruments & Supplies
From Merit Medical Systems, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Merit Medical Systems, Inc.
Latest news
- NEWS Merit Medical Systems, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:MMSI) 2026-11-03 - Seeking Alpha — Seeking Alpha Nov 3, 2026 neutral
- NEWS Merit Medical Systems (NASDAQ:MMSI) beats Q3 2026 sales expectations - StockStory — StockStory Oct 29, 2026 positive
- NEWS Merit Medical Systems (MMSI) reports earnings tomorrow: what to expect - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS Accelerating Organic Growth Propels Merit Medical Systems (MMSI) - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Merit Medical Systems (MMSI) reports earnings tomorrow: what to expect - TradingView — TradingView Oct 28, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-05T11:39:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $90.63, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.4% away). Chart setup: RSI 52 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Analyst target $93.09 (+2.7%), stop $84.67 (−7.0%), A.R:R 0.3:1. Score 5.9/10, moderate confidence.
Analyst target: $93.09 (+2.7% upside). Analyst target $93.09 (+2.7%), stop $84.67 (−7.0%), A.R:R 0.3:1. Stop-loss: $84.67.
Analyst target reached - limited upside remaining; Near 52-week high (4.4% away).
Merit Medical Systems, Inc. trades at a P/E of 33.9 (forward 19.4). TrendMatrix value score: 5.2/10. Verdict: Hold.
18 analysts rate MMSI, with a consensus score of 4.1/5. 12 analysts publish price targets averaging $107.
What does Merit Medical Systems, Inc. do?Merit Medical Systems manufactures proprietary medical devices across two segments — cardiovascular and endoscopy —...
Merit Medical Systems manufactures proprietary medical devices across two segments — cardiovascular and endoscopy — serving interventional, diagnostic, and therapeutic procedures globally. Revenue comes from direct sales to hospitals and physicians in the U.S. (60% of net sales in 2025) and through distributors and OEM partners internationally, with China as the largest non-U.S. market.